← Human Trials & Peer-Reviewed Studies
Vitamin D status, supplementation, and multiple sclerosis: a systematic review and meta-analysis.
Plain-language guide to PMID 41983136 (2026): meta-analysis of Vitamin D, K2, Magnesium and Zinc, multiple sclerosis.
Key Facts
- PMID
- 41983136
- Journal
- Frontiers in immunology
- Year
- 2026
- Study type
- Meta-Analysis
- Authors
- Li Y et al. (9 authors)
- DOI
- 10.3389/fimmu.2026.1775270
What This Paper Covers, in Plain Language
What It Covers
Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis in this meta-analysis publication.
Therefore, their current meta-analysis aims to examine the relationship between serum 25(OH)D levels-and their modulation through supplementation-and multiple sclerosis.
Why It Was Studied
Multiple sclerosis (MS) is a chronic immune-mediated neurodegenerative disorder of the central nervous system and a leading cause of disability among young adults.
The disease exhibits considerable heterogeneity in clinical progression, with some patients experiencing more aggressive disease activity and a rapid decline in quality of life.
Who the Included Studies Covered
The relevant studies about MS and serum 25-hydroxyvitamin D (25(OH)D) level or vitamin D3 supplementation.
This meta-analysis incorporated 40 research examining the correlation between serum 25(OH)D levels and multiple sclerosis, as well as 22 studies investigating the effects of vitamin D3 supplementation on multiple sclerosis.
How the Review Was Done
Comprehensive literature review was performed from conception to November 17, 2025, employing various online databases including PubMed, Cochrane Library, Web of Science, and EMBASE.
What Was Measured
The subject headings attached to it are Vitamin D, Multiple Sclerosis, Dietary Supplements, Vitamin D Deficiency and Cholecalciferol.
The authors tagged it with the keywords MS, VDRpolymorphisms, expanded disability status scale and supplementation.
What This Means in Plain Language
This is a meta-analysis of Vitamin D, K2, Magnesium and Zinc in people with multiple sclerosis.
Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2026 (Frontiers in immunology), a journal based in Switzerland.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.